2026-10-12T10:31:53Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33979903 2026-09-24T05:33:07Z category_19 portal_316 item_type_3 month_year_09_2026

Data Sheet 1_Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes.docx Chia-Yu Kuo (18014107) Jheng-Yan Wu (14632802) Ya-Wen Tsai (4983602) Chih-Cheng Lai (533198) Jiun-Ling Wang (304072) Pharmacology amputation complication diabetes diabetic foot tirzepatide Background<p>Diabetic foot complications affect up to 25% of patients with type 2 diabetes (T2D) and represent a major cause of morbidity. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist - tirzepatide (TZP) has demonstrated superior glycemic control compared with semaglutide however, evidence regarding its effects on diabetic foot complications (DFCs) remains limited.</p>Methods<p>We conducted a retrospective cohort study using the TriNetX network. Adults with T2D initiating TZP, sulfonylurea (SU), dipeptidyl peptidase-4 inhibitors (DPP-4is), sodium–glucose cotransporter-2 inhibitors (SGLT2is), and glucagon-like peptide-1 receptor agonists (GLP-1RAs) between January 2022 and July 2025 were included. Propensity score matching created balanced cohorts for four comparisons. The primary outcome was the risk of DFC - a composite of ulcers, infections, critical limb ischemia, and revascularization or amputation.</p>Results<p>After matching, four cohorts included 141,002 patients per arm (TZP vs. SU), 131,449 patients per arm (TZP vs. DPP-4i), 146,321 patients per arm (TZP vs. SGLT2i), and 97,457 patients per arm (TZP vs. GLP-1RA). Compared with SU, TZP was associated with reduced diabetic foot complications (HR, 0.80; 95% CI, 0.76–0.84). Similar reductions were observed versus DPP-4i (HR, 0.83; 95% CI, 0.78–0.87) and SGLT2i (HR, 0.88; 95% CI, 0.83–0.92). No difference was found versus GLP-1RA (HR, 0.97; 95% CI, 0.91–1.03).</p>Conclusion<p>TZP was associated with a reduction in diabetic foot complications compared with SU, DPP-4i, and SGLT2i, with outcomes similar to GLP-1RA. These findings suggest tirzepatide may be a valuable option for patients at risk of ulceration or amputation.</p> 2026-09-24T05:33:07Z Dataset Dataset 10.3389/fphar.2026.1880132.s001 https://figshare.com/articles/dataset/Data_Sheet_1_Tirzepatide_versus_other_anti-diabetic_agents_for_the_prevention_of_diabetic_foot_complications_in_patients_with_type_2_diabetes_docx/33979903 CC BY 4.0